CO6251262A2 - Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1 - Google Patents

Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1

Info

Publication number
CO6251262A2
CO6251262A2 CO09143477A CO09143477A CO6251262A2 CO 6251262 A2 CO6251262 A2 CO 6251262A2 CO 09143477 A CO09143477 A CO 09143477A CO 09143477 A CO09143477 A CO 09143477A CO 6251262 A2 CO6251262 A2 CO 6251262A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
cycloalkyl
hydrogen
aryl
Prior art date
Application number
CO09143477A
Other languages
English (en)
Inventor
Marc Capet
Nicolas Levoin
Original Assignee
Bioprojet Soc Civ
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ, Sun Pharma Advanced Res Co Ltd filed Critical Bioprojet Soc Civ
Publication of CO6251262A2 publication Critical patent/CO6251262A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)

Abstract

1.- El compuesto de la fórmula (I)(I)en donderepresenta un grupo de oxadiazol 1, 2, 4; X1 es un anillo mono-, bi- o triciclíco seleccionado de un grupo heterocíclico, heteroarilo, arilo o un grupo cicloalquilo que incluye opcionalmente uno o más sistemas insaturados; R1 se selecciona del grupo que consiste de hidrógeno, halo, perhaloalquilo, perhaloalcoxi, arilo, arilalquilo, alquilarilo, alquilo, alquenilo, alquinilo, -N(R2)2 y cicloalquilo que opcionalmente comprende uno o más sistemas insaturados; caracterizado porque el grupo arilo puede fusionarse con un anillo que comprende de 2 a 5 átomos seleccionados de un carbono o heteroátomo; además se caracteriza porque cada R1 se sustituye opcionalmente, desde uno hasta el número máximo de posiciones que pueden ser sustituidas, por un sustituyente seleccionado independientemente de un grupo que consiste en halo, -alquilo, -O-alquilo, cicloalquilo, arilo, arilalquilo, alquilarilo y perhaloalquilo; y cada R2 se selecciona independientemente de hidrógeno, -alquilo, -cicloalquilo, -CO-(O)r-alquilo, -CO-(O)r-cicloalquilo, -O-CO-alquilo, -O-CO- cicloalquilo, en donde r es 0 o 1; Y1 representa una unión o Y1 se selecciona de un grupo formado por -O- ; S(O)q-, caracterizado porque q es 0, 1 o 2; y -C=Q-, en donde Q es O, S, N-R' o N-OR', caracterizado porque R' se selecciona de hidrógeno, -alquilo, -alquenilo, -alquinilo, -alcoxi, -cicloalquilo o -perhaloalquilo; cada porción R1-Y1, idéntica o diferente, representa un grupo que está unido a la estructura de anillo cíclico X1 y m es un entero seleccionado de 1 a 9, caracterizado porque m representa el número de posiciones de X1 sustituidas por una porción R1-Y1. Y2 representa una unión o Y2 se selecciona de un grupo compuesto de -O-; -CH2-; -C(O)O-; -C(O)NH-; -S(O)q-, caracterizado porque q es 0, 1 o 2; y -C=Q-, en donde Q es O, S, N-(R')2 o N-OR', caracterizado porque cada R' se selecciona independientemente de hidrógeno, -alquilo, ...
CO09143477A 2007-06-15 2009-12-15 Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1 CO6251262A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290748A EP2014653A1 (en) 2007-06-15 2007-06-15 Novel dicarboxylic acid derivatives as S1P1 receptor agonists

Publications (1)

Publication Number Publication Date
CO6251262A2 true CO6251262A2 (es) 2011-02-21

Family

ID=38645817

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09143477A CO6251262A2 (es) 2007-06-15 2009-12-15 Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1

Country Status (17)

Country Link
US (1) US8809539B2 (es)
EP (2) EP2014653A1 (es)
JP (1) JP5346016B2 (es)
KR (1) KR20100040853A (es)
CN (1) CN101784535A (es)
BR (1) BRPI0811712A2 (es)
CA (1) CA2693126A1 (es)
CO (1) CO6251262A2 (es)
EA (1) EA018826B1 (es)
IL (1) IL202741A0 (es)
MA (1) MA31447B1 (es)
MX (1) MX2009013733A (es)
NZ (1) NZ581933A (es)
TN (1) TN2009000524A1 (es)
UA (1) UA99132C2 (es)
WO (1) WO2008152149A1 (es)
ZA (1) ZA200908851B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2193126B1 (en) 2007-10-04 2015-06-24 Merck Serono S.A. Oxadiazole diaryl compounds
US8202865B2 (en) * 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
EP2209771A1 (en) * 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl carboxylic acid derivatives
HUE030424T2 (en) 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
BRPI0917923B1 (pt) 2008-08-27 2022-04-05 Arena Pharmaceuticals Inc Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1P RECEPTOR MODULATORS
NZ592748A (en) 2008-10-17 2013-01-25 Akaal Pharma Pty Ltd 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
JP2013521301A (ja) 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス
CN103119038B (zh) * 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
CA2797668A1 (en) 2010-04-27 2011-11-03 Allergan, Inc. 3-(4-((1h-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
ES2539256T3 (es) 2010-07-20 2015-06-29 Bristol-Myers Squibb Company Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
WO2012112841A2 (en) * 2011-02-18 2012-08-23 Abbott Laboratories [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
WO2018119080A1 (en) * 2016-12-21 2018-06-28 Cornell University Compositions and methods for treating hepatic disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN107827837B (zh) * 2017-11-21 2021-09-24 苏州朗科生物技术股份有限公司 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用
SG11202006255UA (en) * 2018-02-02 2020-07-29 Univ Kyoto Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN111803636B (zh) * 2020-07-22 2022-08-30 四川大学 1-磷酸鞘氨醇受体1作为microRNA-9调控血管生成的药物靶点的应用
RU2765464C1 (ru) * 2021-05-20 2022-01-31 Федеральное государственное бюджетное учреждение науки Институт органической химии им. Н.Д. Зеленского Российской академии наук (ИОХ РАН) Способ получения эфиров пиперидин-4,4-дикарбоновых кислот
JP7464075B2 (ja) 2022-04-20 2024-04-09 株式会社大林組 プレストレス構造及びそれを用いたプレキャストコンクリート部材

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) * 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
JP4516430B2 (ja) * 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
PL1650186T3 (pl) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych

Also Published As

Publication number Publication date
EP2170850A1 (en) 2010-04-07
EA018826B1 (ru) 2013-11-29
KR20100040853A (ko) 2010-04-21
EP2170850B1 (en) 2014-09-24
TN2009000524A1 (en) 2011-03-31
US8809539B2 (en) 2014-08-19
JP2010529977A (ja) 2010-09-02
NZ581933A (en) 2012-01-12
UA99132C2 (ru) 2012-07-25
MA31447B1 (fr) 2010-06-01
BRPI0811712A2 (pt) 2014-11-04
EP2014653A1 (en) 2009-01-14
IL202741A0 (en) 2010-06-30
US20100249187A1 (en) 2010-09-30
CN101784535A (zh) 2010-07-21
EA201000024A1 (ru) 2010-06-30
WO2008152149A1 (en) 2008-12-18
MX2009013733A (es) 2010-04-22
AU2008263817A1 (en) 2008-12-18
JP5346016B2 (ja) 2013-11-20
ZA200908851B (en) 2010-07-28
CA2693126A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
CO6251262A2 (es) Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
DOP2023000023A (es) Agonistas del glp-1 heterocíclicos
AR106778A1 (es) Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo
CO6150181A2 (es) Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
PE20040373A1 (es) Composiciones herbicidas que comprenden derivados de isoxazolina
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
PE20110672A1 (es) 4-fenil-1-h-pirazoles insecticidas
CO6220851A2 (es) Compuestos de ciclohexandiona sustituidos en la posicion 5
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
PE20171645A1 (es) Derivados de heterociclos biciclicos condensados sustituidos con 2-(het)arilo como agentes para combatir parasitos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
PE20130155A1 (es) Derivados de ariletinilo
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
CO6290763A2 (es) Derivados de benzamidas, carboxamidas y nicotinamidas como moduladores alostericos positivos y sus composiciones
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
AR063028A1 (es) Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5

Legal Events

Date Code Title Description
FC Application refused